Jeffrey Curtis RADoctor
5 years 8 months ago
My #rheumatology clinics now inundated with patient questions re: #CovidVaccine. I'm looking forward to new #CovidVaccine Guidance expected from the newly-convened #ACR Task Force, forthcoming on February 11th.
Dr. John Cush RheumNow
5 years 8 months ago
Is there such a thing as "Preclinical Lupus" - half to 2/3 of SLE pts had + serologies up to 9 yrs before the Dx @KDAO2011 @UTSWIMchief @UTSWIMchief https://t.co/ThpKjZEG2v
Dr. John Cush RheumNow
5 years 8 months ago
The new ACR/EULAR SLE Classification Criteria 2019 with weighted criteria - need to be ANA+ and have 10 points @UTSWIMchief @UTSWInternalMed https://t.co/TwyUbEOCg2
Dr. John Cush RheumNow
5 years 8 months ago
UT Southwestern Grand Rounds w/ Dr. Kathyrn Dao @KDAO2011 - lecturing on lupus. Showing that the population rate of ANA has increased over time - NHANES shows 44 million in the USA have +ANA! @UTSWInternalMed @UTSWIMchief https://t.co/qU5gzuAD9j
Dr. Jack Cush reviews this past week's journal articles and news features on RheumNow.com. Colchicine, vaccine rollout, risk of RA in endometriosis patients, tREACH trial, lupus nephritis news, rheumatology burnout and more.
Dr. John Cush RheumNow
5 years 8 months ago
QD Clinic - Dadgummit, Where's Waldo's COVID Vaccine?
My rant on the COVID vaccine unavailability, and what we can - and can't - tell patients.
https://t.co/VKrDgvuXqt https://t.co/zuNe8lEaR4
Predictive modeling of data derived from the DANBIO registry (of treated IMID patients) revealed a 4 fold increased risk of serious infection (SIE) in those starting biologic DMARD (bDMARD) treatment. From this large dataset, researchers developed a simple prediction model to estimate future infection risk that may inform shared decision-making in individual patients.
A systematic review by Urowitz and colleagues examined placebo responses in randomized controlled trials of non-renal, non-neuropsychiatric SLE patients showing unexpectedly high placebo responses; with more than one-third of the placebo-treated SLE patients responding by validated outcome measures.
Dr. John Cush RheumNow
5 years 8 months ago
Colchicine suppresses MSU & CA pyrophosphate crystal activation of Nod-Like Receptor Protein 3 (NLRP3) inflammasome, thereby suppressing caspase-1 activation and the subsequent release of IL-1β and IL-18. Great review by Pillinger et al https://t.co/n7MHtSviT5
Dr. John Cush RheumNow
5 years 8 months ago
New download available--Televideo Joint Exam Checklist
https://t.co/XnyCW2eak8 https://t.co/WMdkra6SYv
Dr. John Cush RheumNow
5 years 8 months ago
QD Clinic - Rhabdo or Not
https://t.co/KmKPTaFOtr https://t.co/9AvOIOOmci
Dr. John Cush RheumNow
5 years 8 months ago
Urate Lowering Therapy During Acute Gout
Acute gout has its well-defined protocols, and most state that urate lowering therapy (ULT) should be continued; but does ULT affect outcomes in an acute gout attack?
https://t.co/aDHpU1I2d2 https://t.co/QihJNhMW8L
